Cyclobutanone analogues of ‐lactam antibiotics: ‐lactamase inhibitors with untapped potential? Prarthana Devi and Peter J. Rutledge* Dr Prarthana Devi, Prof. Dr. P. J. Rutledge, School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia, E‐mail:
[email protected]; Tel.: +61 2 9351 5020; Fax: +61 2 9351 3329. Abstract ‐Lactam antibiotics have been used for many years to treat bacterial infections. However the effective treatment of an increasing range of microbial infections is threatened by bacterial resistance to ‐lactams: the prolonged, widespread and at times reckless use of these drugs has spawned widespread resistance, which renders them ineffective against many bacterial strains. The cyclobutanone ring system is isosteric with ‐lactam: in cyclobutanone analogues, the eponymous cyclic amide is replaced with an all‐carbon ring, the amide N substituted by a tertiary C–H to a ketone. Cyclobutanone analogues of various ‐lactam antibiotics have been investigated over the last thirty‐five years, initially as prospective antibiotics in their own right and inhibitors of the ‐lactamase enzymes that impart resistance to ‐lactams, more recently as inhibitors of other serine proteases and mechanistic probes of ‐lactam biosynthesis. Cyclobutanone analogues of the penam ring system are the first reversible inhibitors to demonstrate moderate activity against all classes of ‐lactamase, while other compounds from this family inhibit Streptomyces R61 DD‐carboxypeptidase/transpeptidase, human neutrophil elastase (HNE) and porcine pancreatic elastase (PPE). But has their potential as enzyme inhibitors been fully exploited? Challenges in synthesising diversely functionalised derivatives mean only a limited number and structural diversity of cyclobutanone ‐lactam analogues have been made and evaluated to date.